Globus Medical Inc leadership

David C. Paul is the Chairman of the Board of Directors, having served in this role since the Company's inception in 2003, and is a member of the Board's Compensation Committee and the Nominating and Corporate Governance Committee. Mr. Paul served as our CEO from our inception in 2003 until August 2017, when he transitioned into the role of Executive Chairman. Prior to founding Globus, Mr. Paul was employed at Synthes Holding AG (formerly Synthes-Stratec) in various positions, serving as Director of Product Development for Synthes in his last position, where he was responsible for product development and marketing functions. Mr. Paul is named inventor on over 300 patents and published applications and is the Company's founder and largest stockholder.

Keith W. Pfeil has served as President and CEO of Globus Medical, Inc. since July 2025 and as a member of the Company's Board of Directors since that time. Mr. Pfeil previously served as Chief Operating Officer and Chief Financial Officer beginning in February 2024 and as Chief Financial Officer from August 2019 to February 2024, overseeing a broad portfolio of functions including finance, operations, information technology, quality, strategy, investor relations, tax, pricing, internal audit and business development. He played a leadership role in the Company's strategic combination with NuVasive, Inc. and the subsequent integration of the two organizations. Prior to joining Globus Medical, Mr. Pfeil spent more than 15 years at CSS Industries, Inc., culminating in his service as Executive Vice President and Chief Financial Officer.

David D. Davidar has served on our Board of Directors since 2003 and is a member of the Board's Compensation Committee and our Nominating and Corporate Governance Committee. Mr. Davidar served as our Senior Vice President, Operations from January 2013 until March 2016 and as our Vice President, Operations from 2003 to January 2013. He founded Trinity Axis Inc, a company that designs, develops, and integrates hardware, software, and electronics primarily in the smart vending space, and currently serves as its President and Chief Executive Officer. Mr. Davidar is one of the Company's founders.

Daniel T. Lemaitre has served on our Board of Directors since April 2011 and is a member of the Board's Compensation Committee and Audit Committee. Mr. Lemaitre previously served as the CEO of BlueWind Medical, a neuromodulation company based in Israel, from January 2020 until September 2024 after serving as its Executive Chairman from September 2018 until January 2020, and also served as President and CEO of Direct Flow Medical, White Pine Medical, and CoreValve. From 2005 until March 2008, Mr. Lemaitre was a Senior Vice President at Medtronic, where he led the company's strategic planning and corporate development, and he previously spent 28 years as an investment analyst in the medical device field, including 18 years with SG Cowen and six years with Merrill Lynch.

Ann D. Rhoads has served on our Board of Directors since July 2011 and is the Chairperson of the Board's Audit Committee and a member of its Nominating and Corporate Governance Committee. Ms. Rhoads most recently served as the Chief Financial Officer of Forty Seven, Inc., a clinical-stage biotechnology company, from March 2018 to April 2020, and was previously Executive Vice President and Chief Financial Officer of Zogenix, Inc. from March 2010 through January 2017. From 2000 through the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. She holds a B.S. in finance from the University of Arkansas and an M.B.A. from Harvard Business School.

James R. Tobin has served on our Board of Directors since August 2015 and is a member of the Board's Nominating and Corporate Governance Committee and Compensation Committee, and serves as the Lead Independent Director. Mr. Tobin served as President and CEO of Boston Scientific Corporation from March 1999 to July 2009. Before joining Boston Scientific, Mr. Tobin served as the President and CEO of Biogen, Inc. from 1997 to 1998 and as its Chief Operating Officer from 1994 to 1997, and worked at Baxter International in various capacities from 1972 to 1994, including as its President and Chief Operating Officer from 1992 to 1994. He currently serves as chairman of the board of directors of TransMedics, Inc.

Stephen T. Zarrilli has served on our Board of Directors since May 2019 and is a member of the Board's Audit Committee. Mr. Zarrilli has over 25 years of finance, investment and operating experience in technology and life science enterprises and substantial governance experience with public companies. From July 2018 to March 2020, he served as President and CEO of the University City Science Center, and from 2012 to 2018 he served as President, CEO and Director of Safeguard Scientifics, Inc., which he joined in 2007 as Senior Vice President and Chief Financial Officer. He began his career at Deloitte & Touche LLP.

Robert A. Douglas joined our Board of Directors in December of 2019 and is a member of our Board's Audit Committee. He has over thirty years of experience in medical device technology, with particular expertise in digital health, and from 2012 to 2023 served as the President and Chief Operating Officer in the Office of the CEO for Resmed Inc. Currently, Mr. Douglas serves on the Board of Directors and Audit Committee of PolyNovo Limited. He has an M.B.A. from Macquarie University and a Bachelor of Engineering, Electrical with 1st Class Honors, and a Bachelor of Science, Computer Sciences from the University of New South Wales, Sydney.

Leslie V. Norwalk, Esq. has served as a member of our Board of Directors since September 2023, and previously served on the board of directors of NuVasive from May 2014 to September 2023. Ms. Norwalk is currently strategic counsel to Epstein Becker & Green, EBG Advisors and National Health Advisors, and serves as a healthcare, regulatory and policy advisor to several private equity firms. She previously served the George W. Bush Administration as the acting administrator for the Centers for Medicare & Medicaid Services. Ms. Norwalk earned a B.A., cum laude, in economics and international relations from Wellesley College and a J.D. from the George Mason University School of Law.

Daniel J. Wolterman has served on our Board of Directors since September 2023, and previously served on the board of directors of NuVasive from July 2015 to September 2023 and as board chair from May 2021 to September 2023. Mr. Wolterman is currently CEO of Wolterman Consulting, LLC, and previously served as President and CEO of Memorial Hermann Health System, the largest not-for-profit health system in Southeast Texas, from 2002 until May 2016. He has more than 40 years of experience in the healthcare industry and currently serves on the board of directors of Hyperfine, Inc.

Kelly G. Huller has been the Executive Vice President, General Counsel and Corporate Secretary since December 2018. Ms. Huller began her career at Globus in 2006 as its first in-house counsel and leads the Company's global legal department, overseeing its intellectual property, litigation and corporate legal functions, supporting all regions and business units and having responsibility for corporate and commercial transactions, employment law, risk management, corporate governance and securities matters. Prior to joining Globus, Ms. Huller was a trial attorney at Conrad O'Brien (now Clark Hill) in Philadelphia. She received a B.A. from Pennsylvania State University and earned her J.D. from Temple University.

Kyle R. Kline has served as our Senior Vice President and Chief Financial Officer since July 2025. Kyle previously served as our Senior Vice President of Finance and held roles of increasing responsibility in accounting and finance since joining the Company as Assistant Controller in May 2017, leading the Company's day-to-day accounting, finance, treasury, and tax functions. Kyle joined the Company after nearly 10 years at Deloitte, where he served in several leadership roles in Deloitte's audit practice, most recently as Senior Manager. He holds a Bachelor of Science in accounting from Bloomsburg University.

Daniel T. Scavilla served as the Company's President and Chief Executive Officer until his resignation effective July 18, 2025, and was a named executive officer for 2025. He was identified in the proxy statement's Compensation Discussion and Analysis among the Company's named executive officers as our former Chief Executive Officer and President.